临床数据优异,却惨遭原研药企终止,投资者表示:“我不理解”!2025年5月19日,知名基因编辑公司Prime Medicine公布了旗下Prime Editing(先导编辑)疗法PM359在人类临床试验中的初步数据。该临床数据颇具里程碑意义。这是Prime Editing技术首次被用于治疗人类患者,且PM359临床数据积极。然而,该公司反其道而行之,暂停该临床项目的内部开发,并调整其管线优先顺序,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.